Glucosamine and Chondroitin for Osteoarthritis: History
View Latest Version
Please note this is an old version of this entry, which may differ significantly from the current revision.
Subjects: Pharmacology & Pharmacy
Contributor:
Arrigo Cicero

Glucosamine is a water-soluble amino monosaccharide available in two forms (glucosamine sulphate and glucosamine hydrochloride), which is a normal constituent of glycosaminoglycans (GAGs) in cartilage matrix and in the synovial fluid and consequently present in high quantities in articular cartilage. It is a constituent of keratan sulphate. Chondroitin is a major component of the extracellular matrix of articular cartilage, which played an important role in creating considerable osmotic pressure. In this way, it could provide cartilage with resistance and elasticity to resist tensile stresses during loading conditions.

  • Chondroitin
  • glucosamine
  • chondroprotective effects

1. Glucosamine and Chondroitin

Chondroitin and glucosamine are nutraceuticals commonly used in clinical practice for OA patients for its analgesic and chondroprotective effects [1]. Glucosamine is a water-soluble amino monosaccharide available in two forms (glucosamine sulphate and glucosamine hydrochloride), which is a normal constituent of glycosaminoglycans (GAGs) in cartilage matrix and in the synovial fluid and consequently present in high quantities in articular cartilage. It is a constituent of keratan sulphate. Chondroitin is a major component of the extracellular matrix of articular cartilage, which played an important role in creating considerable osmotic pressure. In this way, it could provide cartilage with resistance and elasticity to resist tensile stresses during loading conditions [2].

2. Mechanisms of Action

Glucosamine and chondroitin act first as anti-inflammatory agents. A study conducted in rats treated with different dosages of glucosamine (20, 40, 80, or 160 mg/kg/day) showed, by the 6th day, the capability of this substance to reduce the levels of proinflammatory cytokines interleukin (IL)-1, IL-6, and tumor necrosis factor (TNF)-α, also preventing the increase in plasma nitrite levels [3]. Similar results were obtained by Li et al., and Waly et al., on mice with monosodium iodoacetate-induced OA in which glucosamine was shown to downregulate serum pro-inflammatory cytokines (IL-1β, IL-6, and TNF-α) and C-reactive protein levels and upregulate the anti-inflammatory cytokines IL-2 and IL-10 levels [4][5]. Oral glucosamine administration is able to suppress the early increase in tumor grown factor (TGF)-β levels in monosodium iodoacetate-induced OA rats [4]. Nevertheless, the precise role of TGF-β in different stages of OA is still unclear as well as the effects of glucosamine on this function required further confirmations [4]. Glucosamine appears to also have immune-modulatory activity by inhibiting the expression and/or activity of catabolic enzymes, such as phospholipase A2, MMPs, or aggrecanases [6].
Both chondroitin and glucosamine sulphate were demonstrated to reduce the activation of the nuclear factor κB (NF-κB) and p38 mitogen-activated protein kinase (MAPK) pathway, which represent a pathway of inflammation in OA [7]. In addition, further studies showed that these molecules prevent the cytokine-induced IL-1β expression by suppressing the demethylation of the IL-1β promoter region [6], inhibiting the lipopolysaccharide (LPS)-induced reactive oxygen species (ROS) generation, nucleotide-binding oligomerization domain-like receptor containing pyrin domain 3 (NLRP3) inflammasome activation and caspase-1 activation, and upregulation and release of IL-1β [8].
Another important activity of both chondroitin and glucosamine concerns its antioxidant properties, which have been reported in several in vitro models [9]. Even though glucosamine hydrochloride and glucosamine sulphate possess antioxidant activity, glucosamine sulphate shows greater antioxidant and radical scavenging activities compared with glucosamine hydrochloride [10].
The reduction of ROS produced during the early OA stage by mechanical stress, trauma, or chemicals is important in order to reduce the cellular damage on the adjacent cartilage and collagen degradation [11]. Glucosamine was shown to bind directly with malondialdehyde (MDA) and block the subsequent formation of MDA adducts and protein cross-linkages and thus prevent lipoprotein oxidation and inhibit MDA adduct formation in the articular chondrocyte cell matrix [12]. Other in vitro studies reported the ability of these molecules to inhibit hydrogen peroxide (H2O2)-mediated membrane lipid peroxidation, protein and DNA oxidation, as well as the intracellular ROS level in chondrocytes, with the upregulation of glutathione (GSH) and other antioxidant enzymes, including superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GPx) in chondrocytes [13]. However, direct evidence of the antioxidant activity of both glucosamine and chondroitin in OA animal models is limited. In a study conducted in the formalin-induced osteoarthritic rat knee joint, the association of glucosamine hydrochloride, chondroitin sulphate, methylsulfonylmethane, Harpagophytum procumbens root extract, and bromelain administered orally for 30 days resulted in a significant reduction in MDA, NO, and 8-hydroxyguanine levels and an increased total GSH level was observed. These reductions were higher in the combination group (with plants) if compared with the administration of glucosamine or chondroitin alone, probably due to the additional analgesic effects [14].
Glucosamine and chondroitin are also known to improve tissue regeneration as demonstrated by different in vivo studies. In New Zealand rabbits with surgical-induced knee joint cartilage damage, treatment with glucosamine sulphate remarkably improved hyaline cartilage regeneration on autologous chondrocyte implantation repair sites, with upregulation of proteoglycans, type II collagen, and GAGs expression compared with autologous chondrocyte implantation alone [15]. In addition, these nutraceuticals simultaneously suppressed the osteoclastic cell differentiation in MC3T3-E1 osteoblasts, downregulating the receptor activator of NF-κB ligand (RANKL) expression [16] and blocked IL-1β-mediated downregulation of type II collagen and aggrecan gene expression and inhibited the MMP-13 gene expression in both normal and OA chondrocytes [17].

3. Efficacy and Safety

Chondroitin and glucosamine were tested in several clinical trials of OA. However, the results remain at least in part contrasting. A recent meta-analysis of 30 randomized clinical trials including 7127 patients showed that chondroitin could alleviate pain symptoms (−0.071, 95%CI: −0.228 to 0.085) and improve physical function (−0.090, 95%CI: −0.242 to 0.061) compared with the placebo [18]. Similar results were shown in a previous meta-analysis in which treatments with glucosamine and chondroitin were found to significantly reduce pain in VAS [weighted mean difference (WMD) −7.41 mm, 95%CI–14.31, –0.51, p = 0.04 and WMD–8.35 mm, 95% CI–11.84, –4.85, p < 0.001, respectively] [19]. Even the meta-analysis by Ogata et al., including 18 RCTs, demonstrated glucosamine’s potential to alleviate knee OA pain [20]. Moreover, Zhu et al., reported the superiority of the combination of glucosamine and chondroitin for pain reduction and joint stiffness in comparison with acetaminophen, even if celecoxib was most likely the best option for knee or hip OA [21]. In a large meta-analysis of 54 randomized clinical trials including 16,427 patients, the effects of glucosamine and chondroitin were compared with conventional treatments. Although, even in this case, celecoxib was considered the best option for pain reduction, only glucosamine plus chondroitin showed a clinically significant improvement from baseline function. In terms of the structure-modifying effect, both glucosamine alone and chondroitin alone achieved a statistically significant reduction in joint space narrowing [22].
However, other studies reported no significant improvement of the OA condition after both glucosamine and chondroitin supplementation. Kwoh et al., did not observe any significant changes in the joint structure in people with chronic knee pain treated with glucosamine 1500 mg/day [23]. In addition, supplementation with chondroitin or glucosamine (1500 mg/day) for 2 years also did not cause remarkable changes in the joint structure of OA patients (aged 45–75 years) [24]. Similar conclusions were obtained from a study regarding 59 people with temporomandibular OA randomly receiving glucosamine sulphate 1200 mg/day or placebo. At the end of the study (six weeks), no significant differences in all signs and symptoms of OA were observed in both groups [25]. In accordance with this data, in a meta-analysis of 17 clinical studies, only seven showed a statistically significant reduction in pain (−0.35, 95%CI = −0.54 to −0.16) and four studies met the review criteria for joint space narrowing (SMD= −0.10, 95%CI = −0.23 to +0.04) [26]. Moreover, several smaller dosages throughout the day of glucosamine seem to be better in pain reduction effects if compared with a single daily large dose (1500 mg) [8].
Both glucosamine and chondroitin were also demonstrated to reduce joint inflammation and oxidative stress. In an RCT including elderly people with temporomandibular joint OA, treatment with an intra-articular hyaluronic acid injection in combination with glucosamine hydrochloride (oral 720 mg for 3 months) was shown to be greatly beneficial by further reducing the IL-6, IL-1β, and TGF-β levels if compared with people treated with only hyaluronic acid injection [27]. Glucosamine sulphate (1500 mg/day) in addition with celecoxib (200 mg/day) supplemented in patients with knee OA for 8 weeks showed a better redox status expressed as higher serum SOD activity and lower serum MDA levels compared with the control group (celecoxib alone) [28].
In conclusion, data indicates that both glucosamine and chondroitin may have a small to moderate effect in reducing OA-related pain and joint inflammation but little effect on joint-space narrowing. The discrepancies in the effectiveness of chondroitin and glucosamine on osteoarthritis between different studies should be further examined.
The supplementation of both chondroitin and glucosamine in the medium term is considered safe and well tolerated. Different studies reported some mild and transitory effects, such as diarrhea, abdominal pain, nausea, and headache. However, there was no significant difference in the comparison between any options (glucosamine alone, chondroitin alone, glucosamine + chondroitin) versus placebo.

This entry is adapted from the peer-reviewed paper 10.3390/ijms222312920

References

  1. DiNubile, N.A. Glucosamine and chondroitin sulfate in the management of osteoarthritis. Postgrad. Med. 2009, 121, 48–50.
  2. Jomphe, C.; Gabriac, M.; Hale, T.M.; Héroux, L.; Trudeau, L.-R.; Deblois, D.; Montell, E.; Vergés, J.; du Souich, P. Chondroitin sulfate inhibits the nuclear translocation of nuclear factor-kappaB in interleukin-1beta-stimulated chondrocytes. Basic Clin. Pharmacol. Toxicol. 2008, 102, 59–65.
  3. Aghazadeh-Habashi, A.; Kohan, M.H.; Asghar, W.; Jamali, F. Glucosamine dose/concentration-effect correlation in the rat with adjuvant arthritis. J. Pharm. Sci. 2014, 103, 760–767.
  4. Li, Y.; Chen, L.; Liu, Y.; Zhang, Y.; Liang, Y.; Mei, Y. Anti-inflammatory effects in a mouse osteoarthritis model of a mixture of glucosamine and chitooligosaccharides produced by bi-enzyme single-step hydrolysis. Sci. Rep. 2018, 8, 5624.
  5. Waly, N.E.; Refaiy, A.; Aborehab, N.M. IL-10 and TGF-beta: Roles in chondroprotective effects of Glucosamine in experimental Osteoarthritis? Pathophysiology 2017, 24, 45–49.
  6. Imagawa, K.; de Andrés, M.C.; Hashimoto, K.; Pitt, D.; Itoi, E.; Goldring, M.B.; Roach, H.I.; Oreffo, R.O. The epigenetic effect of glucosamine and a nuclear factor-kappa B (NF-kB) inhibitor on primary human chondrocytes—implications for osteoarthritis. Biochem. Biophys. Res. Commun. 2011, 405, 362–367.
  7. Wen, Z.H.; Tang, C.C.; Chang, Y.C.; Huang, S.Y.; Hsieh, S.P.; Lee, C.H.; Huang, G.S.; Ng, H.F.; Neoh, C.A.; Hsieh, C.S.; et al. Glucosamine sulfate reduces experimental osteoarthritis and nociception in rats: Association with changes of mitogen-activated protein kinase in chondrocytes. Osteoarthr. Cartil. 2010, 18, 1192–1202.
  8. Chiu, H.W.; Li, L.H.; Hsieh, C.Y.; Rao, Y.K.; Chen, F.H.; Chen, A.; Ka, S.M.; Hua, K.F. Glucosamine inhibits IL-1beta expression by preserving mitochondrial integrity and disrupting assembly of the NLRP3 inflammasome. Sci. Rep. 2019, 9, 5603.
  9. Kuptniratsaikul, V.; Dajpratham, P.; Taechaarpornkul, W.; Buntragulpoontawee, M.; Lukkanapichonchut, P.; Chootip, C.; Saengsuwan, J.; Tantayakom, K.; Laongpech, S. Efficacy and safety of Curcuma domestica extracts compared with ibuprofen in patients with knee osteoarthritis: A multicenter study. Clin. Interv. Aging 2014, 9, 451–458.
  10. Mendis, E.; Kim, M.M.; Rajapakse, N.; Kim, S.K. Sulfated glucosamine inhibits oxidation of biomolecules in cells via a mechanism involving intracellular free radical scavenging. Eur. J. Pharmacol. 2008, 579, 74–85.
  11. Panasyuk, A.; Frati, E.; Ribault, D.; Mitrovic, D. Effect of reactive oxygen species on the biosynthesis and structure of newly synthesized proteoglycans. Free Radic. Biol. Med. 1994, 16, 157–167.
  12. Tiku, M.L.; Narla, H.; Jain, M.; Yalamanchili, P. Glucosamine prevents in vitro collagen degradation in chondrocytes by inhibiting advanced lipoxidation reactions and protein oxidation. Arthritis. Res. Ther. 2007, 9, R76.
  13. Wu, S.; Dai, X.; Shilong, F.; Zhu, M.; Shen, X.; Zhang, K.; Li, S. Antimicrobial and antioxidant capacity of glucosamine-zinc(II) complex via non-enzymatic browning reaction. Food Sci. Biotechnol. 2018, 27, 1–7.
  14. Ucuncu, Y.; Celik, N.; Ozturk, C.; Turkoglu, M.; Cetin, N.; Kockara, N.; Sener, E.; Dundar, C.; Arslan, A.; Dogan, H.; et al. Chondroprotective effects of a new glucosamine combination in rats: Gene expression, biochemical and histopathological evaluation. Life Sci. 2015, 130, 31–37.
  15. Kamarul, T.; Ab-Rahim, S.; Tumin, M.; Selvaratnam, L.; Ahmad, T.S. A preliminary study of the effects of glucosamine sulphate and chondroitin sulphate on surgically treated and untreated focal cartilage damage. Eur. Cells Mater. 2011, 21, 259–271, discussion 270–51.
  16. Igarashi, M.; Sakamoto, K.; Nagaoka, I. Effect of glucosamine, a therapeutic agent for osteoarthritis, on osteoblastic cell differentiation. Int. J. Mol. Med. 2011, 28, 373–379.
  17. Derfoul, A.; Miyoshi, A.D.; Freeman, D.E.; Tuan, R.S. Glucosamine promotes chondrogenic phenotype in both chondrocytes and mesenchymal stem cells and inhibits MMP-13 expression and matrix degradation. Osteoarthr. Cartil. 2007, 15, 646–655.
  18. Zhu, X.; Sang, L.; Wu, D.; Rong, J.; Jiang, L. Effectiveness and safety of glucosamine and chondroitin for the treatment of osteoarthritis: A meta-analysis of randomized controlled trials. J. Orthop. Surg. Res. 2018, 13, 170.
  19. Simental-Mendía, M.; Sánchez-García, A.; Vilchez-Cavazos, F.; Acosta-Olivo, C.A.; Peña-Martínez, V.M.; Simental-Mendía, L.E. Effect of glucosamine and chondroitin sulfate in symptomatic knee osteoarthritis: A systematic review and meta-analysis of randomized placebo-controlled trials. Rheumatol. Int. 2018, 38, 1413–1428.
  20. Ogata, T.; Ideno, Y.; Akai, M.; Seichi, A.; Hagino, H.; Iwaya, T.; Doim, T.; Yamadam, K.; Chen, A.Z.; Li, Y.; et al. Effects of glucosamine in patients with osteoarthritis of the knee: A systematic review and meta-analysis. Clin. Rheumatol. 2018, 37, 2479–2487.
  21. Zhu, X.; Wu, D.; Sang, L.; Wang, Y.; Shen, Y.; Zhuang, X.; Chu, M.; Jiang, L. Comparative effectiveness of glucosamine, chondroitin, acetaminophen or celecoxib for the treatment of knee and/or hip osteoarthritis: A network meta-analysis. Clin. Exp. Rheumatol. 2018, 36, 595–602.
  22. Zeng, C.; Wei, J.; Li, H.; Wang, Y.L.; Xie, D.X.; Yang, T.; Gao, S.G.; Li, Y.S.; Luo, W.; Lei, G.H. Effectiveness and safety of Glucosamine, chondroitin, the two in combination, or celecoxib in the treatment of osteoarthritis of the knee. Sci. Rep. 2015, 5, 16827.
  23. Kwoh, C.K.; Roemer, F.W.; Hannon, M.J.; Moore, C.E.; Jakicic, J.M.; Guermazi, A.; Green, S.M.; Evans, R.W.; Boudreau, R. Effect of oral glucosamine on joint structure in individuals with chronic knee pain: A randomized, placebo-controlled clinical trial. Arthritis Rheumatol. 2014, 66, 930–939.
  24. Fransen, M.; Agaliotis, M.; Nairn, L.; Votrubec, M.; Bridgett, L.; Su, S.; Jan, S.; March, L.; Edmonds, J.; Norton, R.; et al. LEGS study collaborative group. Glucosamine and chondroitin for knee osteoarthritis: A double-blind randomised placebocontrolled clinical trial evaluating single and combination regimens. Ann. Rheum. Dis. 2015, 74, 851–858.
  25. Cahlin, B.J.; Dahlstrom, L. No effect of glucosamine sulfate on osteoarthritis in the temporomandibular joints--A randomized, controlled, short-term study. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 2011, 112, 760–766.
  26. Knapik, J.J.; Pope, R.; Hoedebecke, S.S.; Schram, B.; Orr, R.; Lieberman, H.R. Effects of Oral Glucosamine Sulfate on Osteoarthritis-Related Pain and Joint-Space Changes: Systematic Review and Meta-Analysis. J. Spec. Oper. Med. 2018, 18, 139–147.
  27. Cen, X.; Liu, Y.; Wang, S.; Yang, X.; Shi, Z.; Liang, X. Glucosamine oral administration as an adjunct to hyaluronic acid injection in treating temporomandibular joint osteoarthritis. Oral Dis. 2018, 24, 404–411.
  28. Gang, D.; Xiaguang, C.; Kanghua, Y.; Aiping, W.; Guangxuan, Z. Combined effect of celecoxib and glucosamine sulfate on inflammatory factors and oxidative stress indicators in patients with knee osteoarthritis. Trop. J. Pharm. Res. 2019, 18, 397–402.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.
This entry is offline, you can click here to edit this entry!
Video Production Service
Feedback